ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Animal models"

  • Abstract Number: 2063 • 2018 ACR/ARHP Annual Meeting

    Early Injection of TNF Inhibitor Prevents Spinal Inflammation and Deformity in Curdlan-Induced Spondyloarthritis Animal Model

    Doo-Ho Lim1, Eun-Ju Lee2, Seokchan Hong2, Yong-Gil Kim2, Chang Keun Lee2 and Bin Yoo2, 1Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South)

    Background/Purpose: TNF inhibitors are highly efficient in controlling disease activity and improving functional outcomes as well as quality of life in most ankylosing spondylitis patients;…
  • Abstract Number: 402 • 2017 ACR/ARHP Annual Meeting

    Alteration of the Intestinal Microbiome in the Preclinical Phase of Experimental Arthritis and the Efficacy of Microbiota Modulation in Established Arthritis in Mice

    Rebecca Rogier1, Heather Evans-Marin2, Julia Manasson3, Peter M. van der Kraan4, Wim B. van den Berg5, Marije I. Koenders4, Jose U. Scher6 and Shahla Abdollahi-Roodsaz7,8, 1Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 2Division of Rheumatology, New York University School of Medicine, New York, NY, 3Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 4Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 5Rheumatology Research and Advanced Therapeutics, Radboud University Medical Center, Nijmegen, Netherlands, 6New York University School of Medicine, New York, NY, 7Department of Medicine, Division of Rheumatoogy, New York University School of Medicine, New York, NY, 8Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

    Background/Purpose: The composition of intestinal microbiota is perturbed in patients with new-onset and chronic rheumatoid arthritis (RA). However, it is not known whether the changes…
  • Abstract Number: 1329 • 2017 ACR/ARHP Annual Meeting

    A Quantitative Framework for Evaluating Drug Combination Treatment in Rat Collagen-Induced-Arthritis Model

    Amy Meng1, Julie Di Paolo2, Shringi Sharma3 and Anita Mathias3, 1Clinical Pharmacology, Gilead Sciences, Foster City, CA, 2Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, 3Gilead Sciences, Foster City, CA

    Background/Purpose: Filgotinib (FIL), a JAK1 inhibitor, and GS-9876, a SYK inhibitor, are currently being evaluated as once-daily monotherapy in subjects with rheumatoid arthritis (RA). A…
  • Abstract Number: 2231 • 2017 ACR/ARHP Annual Meeting

    MCC22, a Novel Compound That Targets Both CCR5 and Mu Opioid Receptors, Is Highly Effective in Treating Inflammatory Arthritis Pain

    Raini Dutta1, Mary Lunzer2, Jennifer L. Auger3, Eyup Akgün2, Philip Porthoghese2 and Bryce A. Binstadt3, 1Pediatrics, University of Minnesota, Minneapolis, MN, 2Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, 3Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN

    Background/Purpose: The pain that accompanies rheumatoid arthritis and other chronic inflammatory conditions is difficult to manage. Although opioids provide potent analgesia, chronic opioid use is…
  • Abstract Number: 407 • 2017 ACR/ARHP Annual Meeting

    Selective Inhibition of Tfh Cells By a Small Molecule Inhibitor Abrogates Progression of Experimental Inflammatory Arthritis

    Frank Migliore1, Sedrick Bradley1, Linh Hellmers1, Quretul Quresh2, Jerald M. Zakem3, William E. Davis3, Tamika Webb-Detiege1, Zongbing You4, Robert Quinet2 and Xin Zhang5, 1Ochsner Clinic Foundation, New Orleans, LA, 2Rheumatology, Ochsner Medical Center, New Orleans, LA, 3University of Queensland School of Medicine, Brisbane, Australia, 4Tulane University Health Science Center, New Orleans, LA, 5Laboratory of Cellular Immunology, Institution of Translational Research, Ochsner Medical Center, New Orleans, LA

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by progressive infiltration of the joints by T cells and other leukocytes, production of…
  • Abstract Number: 1335 • 2017 ACR/ARHP Annual Meeting

    p62/SQSTM1 Modulates Bone Erosions in a Murine Model of Rheumatoid Arthritis

    Adelheid Korb-Pap1, Anja Römer-Hillmann1, Marianne Heitzmann1, Masaru Kato2, Kerstin Klein2, Caroline Ospelt2, Steffen Gay3, Susanne Buergis4, Thomas Pap1, Thomas Weide5, André Gessner4 and Hermann Pavenstädt5, 1Institute of Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, 2Center of Experimental Rheumatology, University Hospital Zürich, Zurich, Switzerland, 3Center of Experimental Rheumatology, University Hospital Zürich, Zürich, Switzerland, 4Department of Immunology, University Erlangen, Erlangen, Germany, 5Department of Nephrology and Rheumatology, University Hospital Muenster, Muenster, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is characterised by massive bone erosions leading to irreversible joint destructions. In this context, the multi-adapter protein p62/SQSTM1 is of interest…
  • Abstract Number: 2421 • 2017 ACR/ARHP Annual Meeting

    Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis

    Tomohiro Koga1, Tomohito Sato1, Masataka Umeda2, Shoichi Fukui2, Ayako Nishino1, Shinya Kawashiri2, Naoki Iwamoto2, Kunihiro Ichinose2, Mami Tamai1, Tomoki Origuchi3, Hideki Nakamura2 and Atsushi Kawakami4, 1Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease arising from a breakdown of peripheral tolerance, which leads to aberrant Th1- or Th17-driven immune…
  • Abstract Number: 408 • 2017 ACR/ARHP Annual Meeting

    CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis

    Gianfranco Caselli1, Flora Ferrari1, Eleonora Comi1, Marco Perrella1, Camilla Recordati2, Adriana Grotti1, Rosanna Cavagnoli1, Marco Lanza1 and Lucio C. Rovati3, 1Rottapharm Biotech, Monza, Italy, 2Mouse & Animal Pathology Lab,, Fondazione Filarete, Milano, Italy, Milano, Italy, 3Clinical Research Department, Rottapharm Biotech, Monza, Italy

    Background/Purpose: CR6086, a selective EP4 antagonist, dose-dependently improves disease features in rheumatoid arthritis (RA) models in rodents. Indeed, recent studies highlight the role of the…
  • Abstract Number: 1337 • 2017 ACR/ARHP Annual Meeting

    ASN002, a Novel Dual SYK/JAK Inhibitor, Demonstrates Strong Efficacy in a Rat Model of Collagen-Induced Arthritis

    David Zammit1, Sanjeeva Reddy1, Roger Smith1, Nitin Damle2 and Sandeep Gupta1, 1Asana BioSciences LLC, Lawrenceville, NJ, 2Preclinical R&D, Sun Pharma Advanced Research Co. Ltd, Mumbai, India

    Background/Purpose: Spleen tyrosine kinase (SYK) and Janus kinase (JAK) mediate signaling in immune cells and hematopoietic cells important for the initiation and progression of rheumatoid…
  • Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting

    SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice

    Akiko Nagasu1, Tomoyuki Mukai1, Masanori Iseki2, Hajime Nagasu3, Shunichi Fujita1, Takafumi Mito1, Shoko Kodama1, Yumi Sasae4, Naoki Kashihara3, Katsuhiko Ishihara2, Yasuyoshi Ueki5 and Yoshitaka Morita1, 1Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, 2Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, 3Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, 4Department of Rheumatology, Kawasaki Medical School, Kurashiki Okayama, Japan, 5Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…
  • Abstract Number: 503 • 2017 ACR/ARHP Annual Meeting

    BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis

    JR Burke, KM Gillooly, MA Pattoli, L Cheng, S Skala, EM Heimrich, TL Taylor, C Pulicicchio, DW Kukral, T Petrone, IM Catlett, N Zheng, W Li, SH Watterson and JA Tino, Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in…
  • Abstract Number: 1339 • 2017 ACR/ARHP Annual Meeting

    Role of Hexokinase-2 in Synovial Lining Hypertrophy in Murine Arthritis

    Marta Fernandez Bustmanate1, Jeffrey Smith2, Adam Paul Croft3, Gary S. Firestein4, Chris Buckley5, Shigeki Miyamoto2 and Monica Guma6, 1Medicine, UCSD, San Diego, CA, 2Pharmacology, UCSD, La Jolla, CA, 3Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 4Medicine, University of California San Diego, La Jolla, CA, 5University of Birmingham, Birmingham, United Kingdom, 6Medicine, UCSD, La Jolla, CA

    Background/Purpose: Recent studies indicate that fibroblast-like synoviocyte (FLS) glucose metabolism is altered in rheumatoid arthritis (RA). Hexokinases (HKs) catalyze the first step in glucose metabolism.…
  • Abstract Number: 2574 • 2017 ACR/ARHP Annual Meeting

    Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation

    Mo Yin Mok1, Ka Sin Law2, Wing Yin Kong1, Ge Liu1, Wallace Lau2, C Luo2, FP Huang3, GC Chan4 and Kwok Wah Chan3, 1Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, Hong Kong, 2Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, 3Department of Pathology, University of Hong Kong, Hong Kong, Hong Kong, 4Department of Paediatrics, University of Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: The levels of IL-33, a Th2 promoting cytokine, and the soluble form of its receptor ST2 were reported to be elevated in serum of…
  • Abstract Number: 48 • 2017 ACR/ARHP Annual Meeting

    Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality

    Cedric Lavet, Isabelle Badoud and Patrick Ammann, Division of Bone Diseases, Geneva, Switzerland

    Background/Purpose: Osteochondral unit is a bio composite responsible for an optimal distribution of load during movements and axial compression of a joint. Any alteration of…
  • Abstract Number: 863 • 2017 ACR/ARHP Annual Meeting

    Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology

    Adam Paul Croft1, Joana Campos2, Loriane Savary2, Emma Bishop2, Jason Turner1, Guillaume Desanti2, Francesca Barone3, Andrew Filer3 and Chris Buckley2, 1Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom

    Background/Purpose: Fibroblasts are key effector cells in the persistence of synovial inflammation and joint damage. It is not yet known whether specific subsets of synovial…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology